×
S&P 500   3,897.35 (-0.37%)
DOW   31,404.67 (-0.30%)
QQQ   293.82 (-0.27%)
AAPL   141.70 (+0.03%)
MSFT   265.16 (-0.95%)
META   168.67 (-0.88%)
GOOGL   2,334.00 (-1.08%)
AMZN   114.16 (-1.97%)
TSLA   732.98 (-0.56%)
NVDA   167.07 (-2.45%)
NIO   23.59 (-2.03%)
BABA   119.88 (+1.92%)
AMD   85.69 (-1.60%)
MU   58.66 (+0.38%)
CGC   3.68 (-2.39%)
T   20.97 (-0.10%)
GE   67.04 (-0.06%)
F   11.94 (-0.58%)
DIS   96.58 (-1.23%)
AMC   12.39 (-0.64%)
PFE   51.57 (-0.04%)
PYPL   76.70 (-1.26%)
NFLX   185.50 (-2.80%)
S&P 500   3,897.35 (-0.37%)
DOW   31,404.67 (-0.30%)
QQQ   293.82 (-0.27%)
AAPL   141.70 (+0.03%)
MSFT   265.16 (-0.95%)
META   168.67 (-0.88%)
GOOGL   2,334.00 (-1.08%)
AMZN   114.16 (-1.97%)
TSLA   732.98 (-0.56%)
NVDA   167.07 (-2.45%)
NIO   23.59 (-2.03%)
BABA   119.88 (+1.92%)
AMD   85.69 (-1.60%)
MU   58.66 (+0.38%)
CGC   3.68 (-2.39%)
T   20.97 (-0.10%)
GE   67.04 (-0.06%)
F   11.94 (-0.58%)
DIS   96.58 (-1.23%)
AMC   12.39 (-0.64%)
PFE   51.57 (-0.04%)
PYPL   76.70 (-1.26%)
NFLX   185.50 (-2.80%)
S&P 500   3,897.35 (-0.37%)
DOW   31,404.67 (-0.30%)
QQQ   293.82 (-0.27%)
AAPL   141.70 (+0.03%)
MSFT   265.16 (-0.95%)
META   168.67 (-0.88%)
GOOGL   2,334.00 (-1.08%)
AMZN   114.16 (-1.97%)
TSLA   732.98 (-0.56%)
NVDA   167.07 (-2.45%)
NIO   23.59 (-2.03%)
BABA   119.88 (+1.92%)
AMD   85.69 (-1.60%)
MU   58.66 (+0.38%)
CGC   3.68 (-2.39%)
T   20.97 (-0.10%)
GE   67.04 (-0.06%)
F   11.94 (-0.58%)
DIS   96.58 (-1.23%)
AMC   12.39 (-0.64%)
PFE   51.57 (-0.04%)
PYPL   76.70 (-1.26%)
NFLX   185.50 (-2.80%)
S&P 500   3,897.35 (-0.37%)
DOW   31,404.67 (-0.30%)
QQQ   293.82 (-0.27%)
AAPL   141.70 (+0.03%)
MSFT   265.16 (-0.95%)
META   168.67 (-0.88%)
GOOGL   2,334.00 (-1.08%)
AMZN   114.16 (-1.97%)
TSLA   732.98 (-0.56%)
NVDA   167.07 (-2.45%)
NIO   23.59 (-2.03%)
BABA   119.88 (+1.92%)
AMD   85.69 (-1.60%)
MU   58.66 (+0.38%)
CGC   3.68 (-2.39%)
T   20.97 (-0.10%)
GE   67.04 (-0.06%)
F   11.94 (-0.58%)
DIS   96.58 (-1.23%)
AMC   12.39 (-0.64%)
PFE   51.57 (-0.04%)
PYPL   76.70 (-1.26%)
NFLX   185.50 (-2.80%)
NASDAQ:ESPR

Esperion Therapeutics Stock Forecast, Price & News

$6.46
-0.01 (-0.15%)
(As of 06/27/2022 09:45 AM ET)
Add
Compare
Today's Range
$6.45
$6.57
50-Day Range
$4.77
$6.53
52-Week Range
$3.28
$23.75
Volume
2,184 shs
Average Volume
1.26 million shs
Market Capitalization
$407.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.11
30 days | 90 days | 365 days | Advanced Chart

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Stock Forecast (MarketRank)

Overall MarketRank

1.85 out of 5 stars

Medical Sector

729th out of 1,411 stocks

Pharmaceutical Preparations Industry

354th out of 672 stocks

Analyst Opinion: 3.1Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
Esperion Therapeutics logo

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

ESPR Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
218
Year Founded
N/A

Company Calendar

Last Earnings
5/03/2022
Today
6/27/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$21.11
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+226.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-269.11 million
Net Margins
-263.04%
Pretax Margin
-263.04%

Debt

Sales & Book Value

Annual Sales
$78.45 million
Book Value
($3.23) per share

Miscellaneous

Free Float
61,495,000
Market Cap
$407.03 million
Optionable
Optionable
Beta
0.43














Esperion Therapeutics Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics
or view top-rated stocks.

What is Esperion Therapeutics' stock price forecast for 2022?

8 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' shares. Their ESPR stock forecasts range from $5.00 to $90.00. On average, they expect Esperion Therapeutics' stock price to reach $21.11 in the next year. This suggests a possible upside of 226.8% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Esperion Therapeutics' stock price performed in 2022?

Esperion Therapeutics' stock was trading at $5.00 at the beginning of the year. Since then, ESPR shares have increased by 29.2% and is now trading at $6.46.
View the best growth stocks for 2022 here
.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Esperion Therapeutics
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.03. The biopharmaceutical company earned $18.84 million during the quarter, compared to the consensus estimate of $15.41 million. Esperion Therapeutics's revenue was up 136.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.50) EPS.
View Esperion Therapeutics' earnings history
.

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Sheldon L. Koenig, Pres, CEO & Director (Age 56, Pay $728.91k)
  • Dr. Joanne Micale Foody FACC, M.D., Chief Medical Officer (Age 57, Pay $471.86k)
  • Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
  • Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
  • Mr. Benjamin O. Looker, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 49)
  • Ms. Betty Jean Swartz, Chief Strategy Officer
  • Mr. Eric J. Warren R.Ph., Chief Commercial Officer (Age 49)
  • Ms. April Seiler, Sr. Director of Project Management
  • Roberta Peterson, Sr. Director of National Accounts

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (12.93%), Deep Track Capital LP (9.52%), Vanguard Group Inc. (7.13%), Bellevue Group AG (6.82%), Paradigm Biocapital Advisors LP (1.84%) and Rhenman & Partners Asset Management AB (1.56%). Company insiders that own Esperion Therapeutics stock include Eric Warren, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics
.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Walleye Trading LLC, State Street Corp, Monaco Asset Management SAM, PDT Partners LLC, UBS Group AG, Group One Trading L.P., and Bank of America Corp DE. Company insiders that have sold Esperion Therapeutics company stock in the last two years include Eric Warren, and Sheldon L Koenig.
View insider buying and selling activity for Esperion Therapeutics
or view top insider-selling stocks.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Vanguard Group Inc., Renaissance Technologies LLC, Deep Track Capital LP, Paradigm Biocapital Advisors LP, Northern Trust Corp, Bank of New York Mellon Corp, and Goldman Sachs Group Inc..
View insider buying and selling activity for Esperion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $6.46.

How much money does Esperion Therapeutics make?

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $407.03 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269.11 million in net income (profit) each year or ($6.99) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 218 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for Esperion Therapeutics is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected].

This page (NASDAQ:ESPR) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.